ImmuNext, Inc. logo

ImmuNext, Inc.

ImmuNext is a biopharma company, developing antibody-based therapeutics and novel recombinant fusion proteins to modulate the immune system to treat cancer and autoimmune diseases.

The ImmuNext technology is based on discoveries made in Dr. Noelles labs at the Geisel School of Medicine at Dartmouth and Kings College, London.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://immunext.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1 Medical Center Drive,NH,3756
Lebanon
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/immunext” connections=”true” suffix=””]

In Jan 2017, ImmuNext granted Sanofi an exclusive, worldwide license to develop and commercialize INX-021, a CD40L monoclonal antibody in preclinical development that is overactive in many autoimmune diseases including Lupus and Multiple Sclerosis, with potential milestone payments to ImmuNext under the agreement could total $500 Mn.

In Dec 2016, ImmuNext granted Roche a worldwide, exclusive license to develop and commercialize therapeutics that agonize the V-region immunoglobulin-containing suppressor of T-cell activation (VISTA) signaling pathway, with potential milestone payments to ImmuNext under the agreement could total $400 Mn alongwith up to double digits royalties on sales of products.

In Sep. 2012, ImmuNext grant Janssen Biotech Inc., a worldwide, exclusive clinical development and commercialization rights to the therapeutics that antagonize the V-region immunoglobulin-containing suppressor of T-cell activation (VISTA) signaling pathway. ImmuNext under the agreement got upfront and milestone payments, worth more than $150 Mn USD.

Since Incorporation, ImmuNext has recieved more than $10 Mn in form of various SBIR awards from the National Institutes of Health.